Accelerating Research and Development of Next Generation Malaria Vaccines Against Malaria - A Model for Mosquito-Borne Diseases
This grant funds innovative research and development of advanced malaria vaccines, supporting new technologies to create highly effective vaccines for malaria and other mosquito-borne diseases.
Funder: National Institutes of Health
Due Dates: February 11, 2027 (Application deadline)
Funding Amounts: $4,000,000 estimated total program funding; no cost sharing or matching required
Summary: Supports research and preclinical development of highly efficacious malaria vaccines using technological innovations to achieve long-lasting protection.
Key Information: Clinical trials are not allowed, and applications involving foreign subawards or subcontracts will not be considered for funding.
Description
The National Institutes of Health supports research and/or preclinical development of highly efficacious vaccines against malaria through this R61/R33 funding opportunity. The program emphasizes recent technological innovations, particularly structure-based immunogen design, improved formulations, and combination vaccines, to address one of the deadliest mosquito-borne diseases.
The goal is to achieve long-lasting, highly effective protection that can save lives and strengthen public health security in the United States. Supported work should also serve as a model for developing vaccines against other mosquito-borne diseases, or potentially provide protection against those diseases. This opportunity does not allow clinical trials.
